Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...
The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...
Newly-launched obesity company Kailera Therapeutics has announced the appointment of Jamie Coleman as chief commercial ...
Global commercial executive with expertise across product lifecycle and therapeutic areas leading transformative brands, ...
Hosted on MSN13h
Amgen price target lowered to $295 from $310 at CitiCiti lowered the firm’s price target on Amgen (AMGN) to $295 from $310 and keeps a Neutral rating on the shares. Ahead of the ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Exxon Mobil ...
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
In 2025, Ms. Walker will collaborate with Lilly on certain digital commercial activities. Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for muvalaplin, an ...
Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...
Dr. Jordan accepted a position with Eli Lilly and Co., Agricultural Research Division in Greenfield, Indiana on June 1, 1959, ...
AnalytiXIN has launched a consortium designed to give Indiana researchers better access to health care data—potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback